Evidence map›Paper›PMID 36786988›Full record

ArticleDoklady. Biochemistry and biophysics2022

Association of HLA Class I Genotype with Mortality in Patients with Diabetes Mellitus and COVID-19.

M Yu Shkurnikov, D A Averinskaya, A G Komarov, I A Karbyshev, G I Speshilov, I A Shtinova, D A Doroshenko, V I Vechorko, O M Drapkina

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

M Yu ShkurnikovFaculty of Biology and Biotechnology, HSE University, Moscow, Russia. mshkurnikov@hse.ru.
D A AverinskayaFaculty of Biology and Biotechnology, HSE University, Moscow, Russia.
A G KomarovMoscow City Public Institution of Health Care Diagnostic Center (Laboratory Testing Center) of Moscow Health Department, Moscow, Russia.
I A KarbyshevMoscow City Public Institution of Health Care Diagnostic Center (Laboratory Testing Center) of Moscow Health Department, Moscow, Russia.
G I SpeshilovMoscow City Public Institution of Health Care Diagnostic Center (Laboratory Testing Center) of Moscow Health Department, Moscow, Russia.
I A ShtinovaMoscow City Public Institution of Health Care Diagnostic Center (Laboratory Testing Center) of Moscow Health Department, Moscow, Russia.
D A DoroshenkoMoscow City Public Institution of Health Care Filatov City Clinical Hospital of Moscow Health Department, Moscow, Russia.
V I VechorkoMoscow City Public Institution of Health Care Filatov City Clinical Hospital of Moscow Health Department, Moscow, Russia.
O M DrapkinaNational Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia.
City Clinical Hospital · RUCity Clinical Hospital No15 named. O. M. Filatova · RUNational Research University Higher School of Economics · RUNational Research Center for Preventive Medicine · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous studies showed that diabetes mellitus (DM) increases the risk of death from COVID-19 by five times. It is generally accepted that the high lethality of COVID-19 against the background of DM is due to the main complications of this disease: micro- and macroangiopathies, as well as heart and kidney failure. In addition, it was shown that acute respiratory viral infection increases the production of interferon gamma, increases muscle resistance to insulin, and modulates the activity of effector CD8+ T cells. The ability of CD8+ T cells to recognize SARS-CoV-2-infected cells depends not only on humoral factors but also on individual genetic characteristics, including the individual set of major histocompatibility complex class I (MHC-I) molecules. In this study, the relationship of the MHC-I genotype of patients with DM aged less than 60 years with the outcome of COVID-19 was studied using a sample of 222 patients. It was shown that lethal outcomes of COVID-19 in patients with DM are associated with the low affinity of the interaction of an individual set of MHC-I molecules with SARS-CoV-2 peptides.

Indexed as

COVID-19Diabetes MellitusGenotypeHistocompatibility Antigens Class IHumansMiddle AgedSARS-CoV-2Histocompatibility Antigens Class ICOVID-19diabetes mellitusHLAMHC-I

Identifiers

PMID36786988
PMCPMC9926432
OpenAlexW4320710259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.